Cambrex Corporation, the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), recently announced that it has completed an expansion of cGMP small scale capacity at its Charles City, Iowa plant.
The project has seen the installation of two 500 gallon glass lined reactors and creates a third small scale work center, further increasing flexibility for customer projects.
“Small scale manufacturing has been identified as being a crucial area where capacity is at a premium within the industry, and this investment has been undertaken to increase our flexibility and reduce potential project bottle necks to benefit our customers,” commented Joe Nettleton, Vice President US Operations, Cambrex. “This continues Cambrex’s ongoing commitment to investing in small molecule manufacturing, ensuring that we can meet the challenges of customer project timelines, especially at the key development stages.”
This latest investment follows the completion of an expansion of large scale manufacturing capabilities and an announcement of the construction of a $24M, 4,500 sq. ft. highly potent API (HPAPI) manufacturing facility at Charles City, which is due to open in 2019.
Cambrex’s Charles City, Iowa facility is located on a 45-acre site and manufactures a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances. The facility was recently recognized by the Society of Chemical Manufacturers and Affiliates’ (SOCMA) ChemStewards program, where it exceeded key performance requirements in federal environmental, health, safety and security compliance. As a result, the site qualified for the program’s highest ranking, the Excellence Tier.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, visit www.cambrex.com.
SOURCE: Cambrex Corporation